A 34-year-old female patient was referred to our hospital for investigation of multiple pulmonary nodules, which had been discovered during a regular medical check-up. No abnormal findings were noted in the chest X-ray examination, 12 months prior to her referral. She was being treated with dupilumab subcutaneous injections of 200 mg, every two weeks, for eosinophilic rhinosinusitis for seven months. Apart from a subcutaneous nodule, 10 mm in diameter, on the extensor surface of the right upper arm, which the patient had noticed six months prior to her referral, she complained of no other symptoms. Other than the subcutaneous nodule, the physical examination revealed no anomalous findings. Computerized tomography (CT) examination (Fig. 1), revealed random bilateral pulmonary nodules and multiple mediastinal lymphadenopathies. Bronchoscopy revealed no significant intraluminal findings. Analysis of bronchoalveolar lavage fluid (BALF) indicated an elevation in the number of lymphocytes (monocytes 52%, lymphocytes 47%, and neutrophils 1%). CD4/CD8 ratio was 8.0. There were no bacteria or other acid-fast bacilli cultured in the BALF. Transbronchial lung biopsy (TBLB) reports indicated multiple epithelioid granulomas in the interstitium throughout the alveoli (Fig. 2). Ocular lesions included granulomatous keratic precipitates and snowballs, which are signs of aggregation of inflammatory cells in the vitreous humor, posterior to the lens, suggesting the presence of pan-uveitis. Biopsy of the subcutaneous nodule in the right upper arm revealed epithelioid granulomas (Fig. 3). In addition, the level of serum angiotensin-converting enzyme (ACE) was elevated to 39.5 U/mL, and that of soluble interleukin-2 receptor (sIL-2R) was elevated to 1513 U/mL. These abnormal findings were consistent with sarcoidosis. Since chest X-ray taken five months before she commenced dupilumab therapy did not show any abnormalities, the current findings indicated a DISR caused by dupilumab. We discontinued dupilumab, and started treating her with mepolizumab, an IL-5 inhibitor, for her eosinophilic rhinosinusitis. After cessation of dupilumab, there was a decrease in the levels of serum ACE and sIL-2R. Pulmonary nodules and multiple mediastinal lymphadenopathies also reduced in size (Fig. 4, Fig. 5). She has shown no further signs of the sarcoidosis-like reaction for regularly followed up period.